Mg (magnesium sulfate)
PreclinicalSmall molecule
Mg (magnesium sulfate) is one of 54 small molecule programs targeting Nausea and vomiting. It is currently in Preclinical.
2
Indications
2
Total Trials
1
Active Trials
53
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
78 competitors in Nausea and Vomiting
#DrugCompanyPhaseTrials
1Bridion
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Xylocaine
MMEDRx USA, Inc.
Approved
Duragesic
CCephalon
Approved
Zithromax
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Thalomid
Bristol-Myers SquibbPhase 3
Abraxane
Bristol-Myers SquibbPhase 3
Gemzar
Johnson & JohnsonPhase 3
Megace
Bristol-Myers SquibbPhase 3
Nereus
VVanda Pharmaceuticals
Phase 3
HSK21542
Haisco Pharmaceutical Group Co., Ltd.Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Mg (magnesium sulfate). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- GGangnam Severance Hospital